Research theme for competitive and other funds (1)：
2021 - 2024 悪性リンパ腫におけるT細胞受容体レパトアと免疫微小環境の解析
Papers (31)：
Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Mina Sei, Takuma Matsuo, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, et al. Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study. Cancer medicine. 2023. 12. 17. 17808-17821
Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Shunichi Okumura, Takako Watanabe, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, et al. Hemoglobin-platelet index as a prognostic factor in patients with peripheral T-cell lymphoma. EJHaem. 2023. 4. 3. 656-666
Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Sotaro Goto, Yasuhiko Yamamura, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, et al. Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma. Annals of hematology. 2023. 102. 6. 1485-1500
Taichi Tamura, Masachika Ikegami, Yusuke Kanemasa, Makiko Yomota, Akiko Furusawa, Ryohei Otani, Chiaki Saita, Ichiro Yonese, Tomoko Onishi, Hiroshi Kobayashi, et al. Selection bias due to delayed comprehensive genomic profiling in Japan. Cancer science. 2023. 114. 3. 1015-1025
Yuka Morita, Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Taichi Tamura, Shohei Nakamura, et al. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2023. 64. 7. 586-595
